Versha Banerji, MD FRCPC
DISCLAIMER
The contents of the presentation are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.
SUMMARY
This Canadian discrete choice experiment (DCE) surveyed 64 adults with chronic lymphocytic leukemia (CLL) to assess patient preferences regarding CLL treatment attributes (efficacy, safety, and treatment convenience). Slightly less than half (48%) were diagnosed ≥5 years ago. In terms of treatment experience, 39% of patients were treatment-naïve, while 61% were treatment-experienced (39% first-line, 19% second-line, 3% third-line or later). Among treatment-experienced patients, the most reported prior treatment-related side effects were fatigue or extreme tiredness (67%), diarrhea (44%), nausea and/or vomiting (39%), and neutropenia (31%). Longer progression-free survival (PFS) and reduced quality-of-life (QoL) impact from treatment-related adverse effects (TRAEs) significantly influenced treatment choice (P<.001), whereas treatment convenience contributed minimally. The attributes ranked from most to least important were the QoL impacts of diarrhea (18.6%), headache (18.1%), atrial fibrillation (17.8%), kidney dysfunction (16.3%), and hypertension (15.0%), and those were individually ranked above PFS (13.8%) and treatment convenience (0.4%). Patients demonstrated willingness to trade PFS duration to avoid substantial TRAE burden.
Haitao Wang, PhD
Alvaro Alencar, MD
Nakhle S. Saba, MD
Are you a returning user?
LOGINFor new users, please select your country/region
This website is intended exclusively for healthcare professionals and is provided for scientific exchange and educational purposes only. It is not intended for patients or the general public and does not constitute advertising, promotional activity or medical advice.
Content may include information about products, indications or uses that are not approved in all countries or regions, and may be subject to local regulatory requirements.
By continuing, you confirm that you are a healthcare professional and acknowledge the above.
This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.
This link will take you to a third-party website outside of beonemedaffairs.com.
[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.
By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.
Do you want to leave beonemedaffairs.com
You are now leaving the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed